• HOME
  • PARTNERS
  • NEWS
    • NEWSLETTER
  • JOINT CALLS
    • JOINT TRANSNATIONAL CALL 2022
    • JOINT TRANSNATIONAL CALL 2021
    • JOINT TRANSNATIONAL CALL 2020
    • JOINT TRANSNATIONAL CALL 2019
    • JOINT TRANSNATIONAL CALL 2018
  • FUNDED PROJECTS
  • EP PerMed
    • EP PerMed: Open Consultation for the SRIA
    • Draft Proposal “European Partnership on Personalised Medicine”
    • EP PerMed Information Day
    • EP PerMed Information Sheets
    • Guide to a European Partnership for Personalised Medicine
    • Draft Concept Paper “European Partnership for Personalised Medicine – EP PerMed”
  • PRIVACY
  • FOLLOW US
  • ACCESS FOR MEMBERS
03 May2022

1st First EU Africa PerMed Webinar: “Oncology: Personalised Medicine approach”

Written by Mª Cristina Nieto. Posted in News

Cancer is a major public health problem worldwide and is expected to surpass infectious disease as the leading cause of mortality in Africa within the next two decades.

It is a group of genomic diseases that presents with intra- and inter-population unique phenotypes. At large, the prevention and personalized treatment of cancers have been driven by the understanding of the genetic make-up of the disease of mostly non-African populations. For this, it is needed to address the knowledge gap in understanding the underlying genetic causes of, and genomic alterations associated with, cancer among black Africans.

Lastly, it is related to disparities that include socioeconomic, ethnic, racial, and cultural factors that differ between low and high-income countries.


Retinoblastoma is the most common cancer in the paediatric population and Wilms tumor (WT) is the most common renal malignancy of childhood. Both with global disparities reported indicating highest incidence and lowest survival in sub-Saharan Africa.

Recently studies are focused on identifying the constitutional mutations within the African populations.

Please follow us on @ERANET_PerMed!

Instituto de Salud Carlos III


 height


This project has received funding from the European Union's Horizon 2020 Research and Innovation Programme under Grant Agreement No. 779282